Hyderabad, Aug. 18: The Hyderabad-based Bharat Biotech International Ltd said on Monday it would market recombinant streptokinase, the primary drug for dissolving blood clots, a common occurrence during a heart attack.

According to a company statement, the privately-held BBIL is the first biotechnology company in India to manufacture and market the drug.

The Drug Controller General of India, the national regulatory authority for Indian pharmacopeia, granted the commercial licence to BBIL on August 14, it said.

The recombinant streptokinase is a protein produced from genetically manipulated Escherichia coli. This enzyme is a first line therapy for management of acute myocardial infarction, deep vein thrombosis, arterial occlusion and pulmonary embolism, it added.

“By manufacturing indigenously, we can bring down the cost of this drug, which has been all along imported into India,” it quoted Krishna M. Ella, chairman and managing director of BBIL, as saying.